Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This early phase I trial studies how well atezolizumab in combination with oxaliplatin and
fluorouracil works in treating patients with esophageal or gastroesophageal cancer.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving atezolizumab, oxaliplatin, and
fluorouracil may work better in treating patients with esophageal or gastroesophageal cancer.